Daraxonrasib shows activity in RAS-mutant lung cancer
In an early, single-group study, tumor responses occurred in 31% to 37% across dose ranges, while 54% of 136 evaluated patients had grade 3 or worse adverse events.
The 60-second version
Daraxonrasib produced objective responses in 31% to 37% of dose groups in an early study of previously treated RAS-mutant NSCLC.
Key points
- The analysis included 136 patients receiving daily doses of 300 mg or less.
- Grade 3 or higher adverse events occurred in 54%, and four grade 5 events were reported.
- The open-label, single-group phase 1–2 design had safety as its primary endpoint.
- A randomized phase 3 comparison with docetaxel is needed to test clinical benefit against standard care.
Verdict. The drug showed antitumor activity worth testing, but response rate alone does not establish longer survival or a new standard of care.
The resultTumor responses rose across tested dose ranges
Daraxonrasib, also called RMC-6236, was tested in people with previously treated advanced RAS-mutant non-small-cell lung cancer. Among 136 patients evaluated at daily doses of 300 mg or less, investigator-assessed objective response rates ranged from 31% to 37% across dose groups.
| ≤120 mg daily | 31% had an investigator-assessed objective response. |
|---|---|
| 160–220 mg daily | 34% had an investigator-assessed objective response. |
| 300 mg daily | 37% had an investigator-assessed objective response. |
An objective response means imaging met standardized criteria for complete or partial tumor shrinkage. It does not by itself show that patients lived longer, had better quality of life, or did better than patients receiving another treatment.
The designWhat phase 1–2 can and cannot answer
The multicenter trial escalated and expanded doses from 10 to 400 mg, given orally once daily in 21-day cycles. Safety was the primary endpoint. Objective response and duration of response were secondary endpoints assessed by investigators using RECIST 1.1.
The trial was open-label and single-group. Without random assignment to an active comparator, the response rate cannot establish that daraxonrasib outperforms standard care. It also leaves overall survival and patient-reported benefit unresolved.
SafetySevere adverse events were common
Any-grade adverse events, regardless of attribution, were reported in 99% of patients. Rash, diarrhea, nausea, vomiting, and mucositis or stomatitis each occurred in at least 30%. Grade 3 or higher events occurred in 54%, and four grade 5 events were reported.
| Pneumonia | Grade 3 or higher in 10% of patients. |
|---|---|
| Diarrhea | Grade 3 or higher in 9% of patients. |
| Rash | Grade 3 or higher in 8% of patients. |
| Anemia | Grade 3 or higher in 5% of patients. |
The mechanismA broader way to inhibit active RAS
Daraxonrasib is designed as a RAS(ON) multiselective tri-complex inhibitor. It targets the active, GTP-bound state across mutant and wild-type RAS isoforms, rather than one mutation alone. The broad reach is the scientific attraction; dose selection and effects on normal RAS signaling are part of the safety question.
Evidence ownershipFunding and comparison matter
Revolution Medicines funded the study, and several authors were company employees. That does not negate the measurements, but it strengthens the need for mature follow-up and randomized independent comparison.
The phase 3 RASolve 301 trial is recruiting and plans to compare daraxonrasib with docetaxel in previously treated RAS-mutant NSCLC. Its comparative outcomes will be more informative for treatment decisions than response rate alone.
Tumor shrinkage is a reason to run the definitive trial, not a substitute for one.
Practical meaningThe signal is promising, the standard is not settled
The study supports further testing across RAS mutations while leaving the best dose, comparative benefit, long-term safety and survival effect open. Treatment decisions remain individualized and should be made with an oncology team, not from a response-rate headline.